Current Opinion in Oncology最新文献_第10页

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1097/CCO.0000000000001095

引用次数: 0

Novel PET tracers in breast cancer for treatment optimization: clinical utility and future perspectives. 用于乳腺癌治疗优化的新型 PET 示踪剂：临床实用性和未来展望。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1097/CCO.0000000000001057

Laura Gilardi, Lighea Simona Airò Farulla, Elena Bonatto, Francesco Ceci

{"title":"Novel PET tracers in breast cancer for treatment optimization: clinical utility and future perspectives.","authors":"Laura Gilardi, Lighea Simona Airò Farulla, Elena Bonatto, Francesco Ceci","doi":"10.1097/CCO.0000000000001057","DOIUrl":"10.1097/CCO.0000000000001057","url":null,"abstract":"Purpose of review: There is a critical need for timely and accurate decisions in breast cancer management. This narrative review aims to clarify the potential role of novel PET tracers in optimizing treatment strategies for different breast cancer subtypes.Recent findings: 2-deoxy-2-[18F]-fluoro-D-glucose PET/computed tomography (FDG PET/CT) has a pivotal role in response assessment in metastatic breast cancer, despite its limitations in certain histological and molecular subtypes. Further PET radiopharmaceuticals have been proposed to address these clinical needing.Summary: FES PET/CT demonstrates its usefulness in assessing ER expression and predicting response to therapy in luminal breast cancer, with implications for treatment optimization and monitoring. In HER2-positive and HER2-low breast cancer, HER2-targeted PET tracers show potential in assessing HER2 status, while their accuracy in predicting response to targeted therapies is still debated. PARP-targeted PET imaging holds potential for selecting patients for PARP inhibitors treatments, particularly in triple-negative breast cancer (TNBC), where imaging tools are crucial due to the absence of specific targets. Immunotherapy and antibody-drug conjugates (ADCs) are emerging treatment options for TNBC, and PET imaging targeting immune checkpoints could aid in treatment selection and response monitoring. The dynamic role of PET/CT imaging in tailoring breast cancer treatments requires further multidisciplinary research to validate the clinical utility of targeted tracers.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"514-520"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives. 口服选择性雌激素受体降解剂时代的早期乳腺癌内分泌治疗：挑战与未来展望。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1097/CCO.0000000000001085

Liliana Ascione, Grazia Castellano, Giuseppe Curigliano, Paola Zagami

{"title":"Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.","authors":"Liliana Ascione, Grazia Castellano, Giuseppe Curigliano, Paola Zagami","doi":"10.1097/CCO.0000000000001085","DOIUrl":"10.1097/CCO.0000000000001085","url":null,"abstract":"Purpose of review: Growth and survival of hormone receptor positive breast cancer cells are dependent on circulating hormones (e.g., estrogen and progesterone). Endocrine therapy improved outcomes in both early and advanced hormone receptor positive breast cancer. These treatments include drugs with different mechanisms of action, namely selective estrogen receptor modulators (SERM), aromatase inhibitors, and selective estrogen receptor degraders (SERDs). SERDs represent estrogen receptor antagonists, favoring its degradation and thus interfering with proliferation genes transcription and activation. Fulvestrant is the first approved SERD, administered intramuscularly for treating advanced breast cancer.Recent findings: Oral SERDs have been tested to overcome the limitation of the intramuscular administration, and to increase SERD bioavailability. Recently, an oral SERD, Elacestrant, has been approved by the Food and Drug Administration (FDA) for patients carrying an ESR1 mutation. In fact, oral SERDs seem to be effective in tumors harboring ESR1 mutations, a well known mechanism of resistance to endocrine therapy (especially aromatase inhibitors).Summary: More recently, oral SERDs have been tested in patients with early hormone receptor positive breast cancer, although their impact on survival and in this curative setting compared to standard endocrine therapy still needs to be elucidated. The best timing and duration of SERD administration and specific biomarkers in (neo)adjuvant setting remain largely unknown.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"465-473"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-reported outcomes in neuro-oncology. 神经肿瘤学的患者报告结果。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-10 DOI: 10.1097/CCO.0000000000001078

Josien C C Scheepens, Martin J B Taphoorn, Johan A F Koekkoek

{"title":"Patient-reported outcomes in neuro-oncology.","authors":"Josien C C Scheepens, Martin J B Taphoorn, Johan A F Koekkoek","doi":"10.1097/CCO.0000000000001078","DOIUrl":"10.1097/CCO.0000000000001078","url":null,"abstract":"Purpose of review: To provide up-to-date evidence on patient-reported outcomes (PROs) in neuro-oncology, with a focus on the core constructs of health-related quality of life (HRQoL) and the use of PROs in clinical trials and clinical practice.[Supplemental Digital Content: Video Abstract PROs in Neuro-Oncology.mov].Recent findings: PROs are gaining importance in brain tumor research and medical care. For patients with a brain tumor, core PRO constructs are pain, difficulty communicating, perceived cognition, seizures, symptomatic adverse events, physical functioning and role and social functioning, which are assessed through patient-reported outcome measures (PROMs). Initiatives have been taken to improve the reliability and robustness of PRO data, including standardization of items included in clinical trial protocols (the SPIRIT-PRO extension) and formulation of PRO priority objectives for use in clinical trials (the SISAQOL-Innovative Medicines Initiative). In brain tumor patients with cognitive impairment, caregiver-reported outcomes may complement or replace PROs to increase accuracy. The next key challenge will be to widely implement PROs and apply PRO data in clinical practice to benefit patients with brain tumors.Summary: PROs are clinically relevant endpoints providing information only known by the patient. Standardization of the use of PROs in clinical trials and wide implementation in clinical practice is needed to improve HRQoL of brain tumor patients.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"560-568"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Controversies on chemotherapy for early HR+/HER2- breast cancer: the role of anthracyclines and dose intensification. 早期 HR+/HER2- 乳腺癌化疗的争议：蒽环类药物和剂量强化的作用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1097/CCO.0000000000001062

Francesca Poggio, Chiara Molinelli, Irene Giannubilo, Matteo Lambertini, Eva Blondeaux

{"title":"Controversies on chemotherapy for early HR+/HER2- breast cancer: the role of anthracyclines and dose intensification.","authors":"Francesca Poggio, Chiara Molinelli, Irene Giannubilo, Matteo Lambertini, Eva Blondeaux","doi":"10.1097/CCO.0000000000001062","DOIUrl":"10.1097/CCO.0000000000001062","url":null,"abstract":"Purpose of review: Use of adjuvant chemotherapy significantly reduces the risk of recurrence and improves overall survival (OS) in patients with early-stage breast cancer. However, few data are available on the efficacy of different adjuvant chemotherapy regimens and schedules in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. We aim to summarize the available evidence on the efficacy of adjuvant anthracycline-based chemotherapy and of the dose-dense schedule in this specific patient population. Moreover, current controversies in the management of patients with early-stage HR+/HER2- breast cancer are discussed.Recent findings: Patient-level meta-analysis evaluating the role of the addition of an anthracycline to taxane-based chemotherapy showed that recurrence rate was lower among patients receiving anthracycline-based treatment.Patient-level meta-analysis evaluating the role of different schedules of chemotherapy administration showed that the use of adjuvant dose-dense chemotherapy is associated with significant reduction in breast cancer recurrences and breast cancer mortality. Less evidence is available in the neoadjuvant setting.Summary: For patients with high-risk HR+/HER2- breast cancer, (neo) adjuvant anthracycline and taxane-based chemotherapy, and a dose-dense regimen should still be considered the standard of care. However, in patients with intermediate risk breast cancer candidates to chemotherapy, anthracycline-free regimens could be considered the preferred treatment option.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"495-502"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy in brain tumors: moving on, slowly. 脑肿瘤的液体活检：缓慢前行。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-10 DOI: 10.1097/CCO.0000000000001079

Giulia Berzero, Valentina Pieri, Leonardo Palazzo, Gaetano Finocchiaro, Massimo Filippi

{"title":"Liquid biopsy in brain tumors: moving on, slowly.","authors":"Giulia Berzero, Valentina Pieri, Leonardo Palazzo, Gaetano Finocchiaro, Massimo Filippi","doi":"10.1097/CCO.0000000000001079","DOIUrl":"10.1097/CCO.0000000000001079","url":null,"abstract":"Purpose of review: Due to limited access to the tumor, there is an obvious clinical potential for liquid biopsy in patients with primary brain tumors. Here, we review current approaches, present limitations to be dealt with, and new promising data that may impact the field.Recent findings: The value of circulating tumor cell-free DNA (ctDNA) in the cerebrospinal fluid (CSF) for the noninvasive diagnosis of primary brain tumors has been confirmed in several reports. The detection of ctDNA in the peripheral blood is desirable for patient follow-up but requires ultrasensitive methods to identify low mutant allelic frequencies. Digital PCR approaches and targeted gene panels have been used to identify recurrent hotspot mutations and copy number variations (CNVs) from CSF or plasma. Tumor classification from circulating methylomes in plasma has been actively pursued, although the need of advanced bioinformatics currently hampers clinical application. The use of focused ultrasounds to open the blood-brain barrier may represent a way to enrich of ctDNA the peripheral blood and enhance plasma-based liquid biopsy.Summary: Monitoring CNVs and hotspot mutations by liquid biopsy is a promising tool to detect minimal residual disease and strengthen response assessment in patients with primary brain tumors. Novel methods to increase the relative and/or absolute amount of ctDNA can improve the clinical potential of plasma-based liquid biopsies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"521-529"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When do I ask for a DNA methylation array for primary brain tumor diagnosis? 诊断原发性脑肿瘤时何时需要 DNA 甲基化阵列？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-22 DOI: 10.1097/CCO.0000000000001089

Valeria Barresi, Pietro Luigi Poliani

{"title":"When do I ask for a DNA methylation array for primary brain tumor diagnosis?","authors":"Valeria Barresi, Pietro Luigi Poliani","doi":"10.1097/CCO.0000000000001089","DOIUrl":"10.1097/CCO.0000000000001089","url":null,"abstract":"Purpose of review: Despite remarkable advances in molecular characterization, the diagnosis of brain tumors remains challenging, particularly in cases with ambiguous histology or contradictory molecular features. In this context, DNA methylation profiling plays an important role in improving diagnostic and prognostic accuracy. This review aims to provide diagnostic guidance regarding when DNA methylation arrays represent a useful tool for the diagnosis of primary brain tumors.Recent findings: Large-scale profiling has revealed that DNA methylation profiles of brain tumors are highly reproducible and stable. Therefore, DNA methylation profiling has been successfully used to classify brain tumors and identify new entities. This approach seems to be particularly promising for heterogeneous groups of tumors, such as IDH -wildtype gliomas, and glioneuronal and embryonal tumors, which include a variety of entities that are still under characterization.Summary: As underlined in the fifth edition of the WHO classification of central nervous system tumors, the diagnosis of brain tumors requires the integration of histological, molecular, clinical, and radiological features. Although advanced imaging and histological examination remain the standard diagnostic tools, DNA methylation analysis can significantly improve diagnostic accuracy, with a substantial impact on patient management.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"530-535"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances. 转移性乳腺癌中的抗体-药物共轭物：排序、组合和抗药性。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-05 DOI: 10.1097/CCO.0000000000001087

Lorenzo Guidi, Laura Boldrini, Dario Trapani, Giuseppe Curigliano

{"title":"Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances.","authors":"Lorenzo Guidi, Laura Boldrini, Dario Trapani, Giuseppe Curigliano","doi":"10.1097/CCO.0000000000001087","DOIUrl":"10.1097/CCO.0000000000001087","url":null,"abstract":"Purpose of review: Significant advancements have been made in treating metastatic breast cancer (MBC) with antibody drug conjugates (ADCs). However, due to the development of resistance, patients experience disease progression. The aim of this review is to summarize current evidence on ADCs sequencing strategies and combination approaches in the treatment of MBC.Recent findings: Concerning HER2 positive MBC, current evidence on the optimal ADC-sequencing is primarily about T-DXd, which demonstrated therapeutic value when used post-T-DM1. Conversely, data are limited about the reverse sequence. Similarly, in HER2-negative MBC, recent studies evaluated the sequential use of Sacituzumab Govitecan and T-DXd, which was associated with poor responses. Retrospective analyses have not demonstrated an optimal sequencing strategy for ADCs, and it is still very unclear whether switching the payload or targeting a different antigen may represent the best approach. Combinations may better overcome ADC resistance: interesting data associating immunotherapy or tyrosine kinase inhibitors to ADCs appear promising, albeit data are still immature.Summary: In MBC, ADCs have expanded treatment options but their sequential use requires further study. Evidence suggests that sequencing ADCs with similar payloads is ineffective, though current data are inconclusive. More research is needed to optimize treatment strategies, including potential combination therapies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"487-494"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of melflufen and peptide-conjugates in multiple myeloma. 麦氟芬和多肽结合剂在多发性骨髓瘤中的新作用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-21 DOI: 10.1097/CCO.0000000000001090

Nour Moukalled, Iman Abou Dalle, Jean El Cheikh, Yishan Ye, Florent Malarad, Mohamad Mohty, Ali Bazarbachi

{"title":"The emerging role of melflufen and peptide-conjugates in multiple myeloma.","authors":"Nour Moukalled, Iman Abou Dalle, Jean El Cheikh, Yishan Ye, Florent Malarad, Mohamad Mohty, Ali Bazarbachi","doi":"10.1097/CCO.0000000000001090","DOIUrl":"10.1097/CCO.0000000000001090","url":null,"abstract":"Purpose of review: The past two decades have witnessed an impressive expansion in the treatment landscape of multiple myeloma, leading to significant improvements in progression-free; as well as overall survival. However, almost all patients still experience multiple relapses during their disease course, with biological and cytogenetic heterogeneity affecting response to subsequent treatments. The purpose of this review is to provide a historical background regarding the role of alkylating agents and an updated data regarding the use of peptide-drug conjugates such as melflufen for patients with multiple myeloma.Recent findings: The combination of daratumumab-melflufen-dexamethasone evaluated in the LIGHTHOUSE study showed a statistically significant improvement in progression-free survival compared to single-agent daratumumab (not reached vs. 4.9 months respectively; P = 0.0032), with improvement in overall response rate to 59% vs. 30% respectively; P = 0.03.Summary: There have been an interest in developing and utilizing peptide-drug conjugates such as melflufen for treatment of patients with multiple myeloma, especially in the relapsed setting given historical results with alkylating agents, the use of which has been limited by dose-related toxicities in a disease that remains largely incurable. Single agent melflufen initially showed promising results especially in specific subgroups of heavily pretreated patients before the decision to suspend all clinical trials evaluating this agent after results from the OCEAN phase 3 trial. Subsequent reported analyses especially for melflufen-based combinations appear promising and suggest a potential use of peptide-drug conjugates provided optimal patient selection, as well as identification of the best companion agent.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"583-592"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarker-directed therapy in multiple myeloma. 多发性骨髓瘤的生物标志物导向疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-22 DOI: 10.1097/CCO.0000000000001091

Adam Bryant, Hang Quach

{"title":"Biomarker-directed therapy in multiple myeloma.","authors":"Adam Bryant, Hang Quach","doi":"10.1097/CCO.0000000000001091","DOIUrl":"10.1097/CCO.0000000000001091","url":null,"abstract":"Purpose of review: Multiple myeloma is currently treated with a one-size-fits-all approach despite significant heterogeneity in patient outcomes and disease molecular constitution. A personalised approach would tailor therapy to unique patient or disease characteristics.Recent findings: Well established prognostic biomarkers such as cytogenetic risk and patient frailty status are being evaluated as potential predictive biomarkers. Specifically, treatment intensity can be augmented in high-risk patients or conversely attenuated in those at lower risk or lower ability to withstand treatment toxicities. Alternatively, targeted therapy can be rationally designed to exploit vulnerable pathways in myeloma cells as identified using predictive biomarkers. The t(11;14) translocation, found in approximately 15-20% of myeloma cases, is a leading biomarker for response to BCL-2 inhibitors such as venetoclax.Summary: Active research efforts exploring venetoclax combination therapies, as well as new generation BCL-2 inhibitors are underway. Following the development of venetoclax, numerous other cellular pathways are under investigation as candidate predictive biomarkers to rationally inform newer targeted therapies in myeloma.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"600-609"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0